The global anticoagulants market is witnessing unprecedented growth, driven by a rising prevalence of cardiovascular diseases, venous thromboembolism (VTE), and atrial fibrillation. As the aging population increases worldwide, the demand for effective stroke prevention and thrombosis management has skyrocketed. Modern medicine is shifting from traditional Warfarin to Direct Oral Anticoagulants (DOACs) like Rivaroxaban and Apixaban, which require high-precision chemical synthesis and reliable raw material supply chains.
Hangzhou Jeci Biochem Technology Co., Ltd. is located in Hangzhou, Zhejiang Province. We are committed to sales of active pharmaceutical ingredients, pharmaceutical intermediates, nutritional products and food additives, cooperative R & D, custom manufacturing, sales and service as well as import of these kinds of materials.
In China, we have a strong collaborative R&D team, working in depth with new drug research institutes and multiple custom processing plants. We have very good domestic sales channels and have long-term relationships with domestic companies, including product applications, technology transfer, product supply, custom processing, and exclusive agents for multiple products in multiple regions.
Our facility specializes in the complex synthesis required for next-generation anticoagulants. We provide essential substances for the production of advanced intermediates that meet international pharmacopeia standards. By utilizing cutting-edge batch processing and a rigorous quality management system, we ensure that every gram of product supports the global effort to combat coagulation-related disorders.
Large pharmaceutical enterprises in Europe and North America are increasingly looking for strategic partners in China to optimize their supply chain resilience. The trend is moving towards "Integrated Manufacturing," where the supplier doesn't just provide a powder, but offers full technological support, documentation (DMF/CEP), and scalability.
At Jeci Biochem, we bridge this gap by providing factory quality management system certification consulting services, ensuring our international partners receive products that are compliant with global regulatory bodies.
Anticoagulants and their intermediates are not just clinical necessities; they are industrial benchmarks of chemical engineering. Our products are widely used in the following aspects:
Internationally, we have long-term trade relations with India, Southeast Asia, South Korea, Japan and other markets. Our localized application strategy involves providing product registration, consulting, and sales channel expansion services for overseas companies looking to penetrate the vast Chinese market.
We are able to assemble and produce larger quantities of intermediates and provide some advanced, convenient manufacturing capabilities, including batch processing and customization. For the company's main product intermediates: We can maximize our advantages, meet the requirements of most customers and complete the task within the specified time limit.
The next frontier in anticoagulant manufacturing lies in AI-driven synthesis and Green Chemistry. By reducing waste and optimizing catalyst usage, manufacturers in China are lowering the environmental footprint of API production. Jeci Biochem is at the forefront of this transition, investing in R&D that prioritizes both efficacy and sustainability. As we continue to serve the global market, our focus remains on providing the "building blocks" of health through innovation and reliability.
Whether you are a pharmaceutical company in India seeking high-quality intermediates or a research institute in Europe looking for a custom manufacturing partner, our team is equipped to deliver excellence.
SJ medical